Yang Jing, Yu Xiaojuan, Hu Nan, Su Tao
Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; Renal Pathology Center, Institute of Nephrology, Peking University, Beijing, China; Renal Division, Department of Medicine, The First People's Hospital of Guiyang, Guiyang, Guizhou Province, China.
Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; Renal Pathology Center, Institute of Nephrology, Peking University, Beijing, China.
Am J Med Sci. 2022 Jan;363(1):33-41. doi: 10.1016/j.amjms.2021.10.009. Epub 2021 Oct 21.
Polycythemia vera (PV) is a common type of Philadelphia chromosome-negative chronic myeloproliferative disorder. PV-associated kidney disease is rarely reported and remains poorly understood. It has been observed that chronic kidney disease could be a risk factor for poor prognosis in PV.
We retrospectively analyzed the clinicopathological features of renal presentations in eight patients with confirmed PV-associated kidney disease.
The eight patients were 6 males and 2 females, with a mean age of 46.4 ± 16.8 years. Six patients had a history of PV, with a duration range 0.5-16 years. The other two patients were newly diagnosed with PV simultaneously with glomerular disease. Seven patients conducted a JAK2 V617F mutation test, with a positive result in five. Proteinuria and renal dysfunction were the patients' main complaints, with only one having nephrotic syndrome and three having microscopic hematuria. The level of proteinuria ranged from 0.52-10.96 g/day. Three patients had advanced chronic kidney disease (CKD), two in stage 3b and one in stage 4, but only one patient had anemia. Three patients had monoclonal immunoglobulinemia, one patient with immunoglobulin (Ig) G kappa plus light chain lambda, one patient with IgG kappa, and one patient with IgG lambda. Five patients underwent a renal biopsy. The pathological diagnosis was IgA nephropathy in three, non-IgA mesangial proliferative glomerulopathy in one, and glomerular hypertrophy with ischemic renal injury in one patient. Glomerular ischemia, ischemic shrinkage, focal segmental sclerosis, and glomerulomegaly were common pathological features. Glomerular crescents and endocapillary proliferation were also observed. All patients were administered hydroxyurea, and seven were administered renin-angiotensin system inhibitors. During follow-up, one patient with uncontrolled PV developed secondary myelofibrosis and died, three patients were lost to follow-up, and four patients remained alive with CKD.
Patients with untreated or uncontrolled PV could have massive proteinuria and advanced CKD, pathologically showing ischemic, sclerosing glomerular lesions with hypercellurity, glomerular crescents and endocapillary proliferation. IgA nephropathy was most commonly diagnosed. These findings deserve attention because early screening and effective control of PV may benefit the long-term kidney prognosis.
真性红细胞增多症(PV)是费城染色体阴性慢性骨髓增殖性疾病的常见类型。PV相关的肾脏疾病鲜有报道,目前仍了解不足。据观察,慢性肾脏病可能是PV预后不良的一个危险因素。
我们回顾性分析了8例确诊为PV相关肾脏疾病患者肾脏表现的临床病理特征。
8例患者中男性6例,女性2例,平均年龄46.4±16.8岁。6例患者有PV病史,病程0.5 - 16年。另外2例患者在诊断肾小球疾病的同时新诊断为PV。7例患者进行了JAK2 V617F突变检测,5例结果为阳性。蛋白尿和肾功能不全是患者的主要症状,仅1例患有肾病综合征,3例有镜下血尿。蛋白尿水平为0.52 - 10.96g/天。3例患者患有晚期慢性肾脏病(CKD),2例为3b期,1例为4期,但仅1例患者有贫血。3例患者有单克隆免疫球蛋白血症,1例为免疫球蛋白(Ig)G κ加轻链λ,1例为IgG κ,1例为IgG λ。5例患者接受了肾活检。病理诊断为3例IgA肾病,1例非IgA系膜增生性肾小球病,1例肾小球肥大伴缺血性肾损伤。肾小球缺血、缺血性萎缩、局灶节段性硬化和肾小球肿大是常见的病理特征。还观察到肾小球新月体和毛细血管内增生。所有患者均接受了羟基脲治疗,并对7例患者使用了肾素 - 血管紧张素系统抑制剂。随访期间,1例PV未得到控制的患者发展为继发性骨髓纤维化并死亡,3例患者失访,4例CKD患者存活。
未经治疗或未得到控制的PV患者可能出现大量蛋白尿和晚期CKD,病理表现为缺血性、硬化性肾小球病变伴细胞增多、肾小球新月体和毛细血管内增生。最常诊断为IgA肾病。这些发现值得关注,因为早期筛查和有效控制PV可能有利于肾脏的长期预后。